与左心室辅助器件的医院前经验
Emily L Larson1, Reed Jenkins1, Alexandra Rizaldi1
1Division of Cardiac Surgery, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
The Journal of surgical research
|December 19, 2025
概括
患有左心室辅助器件 (LVAD) 的患者往往需要紧急医疗服务 (EMS),并且存在严重疾病. 这突显了对LVAD患者EMS护理的关键差距,需要改善教育和合作.
科学领域:
- 心脏病学 心脏病学
- 紧急医疗 紧急医疗
- 医疗器械 医疗器械
背景情况:
- 越来越多地使用左心室辅助器件 (LVAD) 治疗心力衰竭.
- 越来越需要紧急医疗服务 (EMS) 来管理LVAD患者.
研究的目的:
- 审查通过EMS运输的LVAD患者的特征和结果.
- 为了确定EMS对LVAD患者的护理方面的差距.
主要方法:
- 从2017年到2021年,对25名LVAD患者的75次EMS运输进行了回顾性审查.
- 分析患者的LVAD特征,EMS干预措施和患者的治疗结果.
主要成果:
- LVAD患者经常出现高急性疾病 (例如,胸痛),其中8%是立即危及生命的.
- 在EMS运输后的一年生存率为74.8%,其中39%在30天内返回ED.
- 在EMS的LVAD评估 (24%),LVAD团队咨询 (8%) 和医院通知 (56%) 中发现了漏洞.
结论:
- LVAD患者经常向EMS提出高敏度,高死亡率和频繁的ED回归.
- 通过加强临床医师教育和机构间合作伙伴关系,有很大的机会改善EMS护理.
- 迫切需要改善对管理LVAD患者的EMS人员的协议和培训.
相关概念视频
Cardiomyopathy V: Interprofessional Care
313
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
313
Heart Failure VI: Adjunct Therapies
235
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
235
Cardiac Catheterization III: Left Heart Catheterization
526
Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
526
Cardiomyopathy VII: Pre and Post Operative Nursing Management
257
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
257
Cardiac Catheterization II: Right Heart Catheterization
741
Right Heart Catheterization: An OverviewRight heart catheterization is an invasive diagnostic procedure that measures right-sided cardiac and pulmonary artery pressures, calculates cardiac output, and identifies intracardiac shunts. It provides detailed hemodynamic data essential for diagnosing and managing various cardiovascular conditions, such as pulmonary hypertension.Access SitesCommon access sites for right heart catheterization include the internal jugular vein in the neck region, the...
741
Cardiomyopathy II: Dilated Cardiomyopathy
436
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
436


